A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Shouwei Zhao
- Phone Number: 0518-82342973
- Email: shouwei.zhao@hengrui.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Zhongshan Hospital
-
Contact:
- Jianming Guo, Doctor
- Phone Number: +86-13681971306
- Email: Guo.jianming@zs-hospital.sh.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;
- ≥18 years of age, either sex;
- Previous pathological biopsy was diagnosed as intermediate or high-risk NMIBC ;
- ECOG performance status of 0-1;
- Life expectancy ≥ 2 years;
- Adequate bone marrow and organ function.
Exclusion Criteria:
- Received TURBT or other surgical treatment or radiotherapy for bladder lesions within 2 weeks before the first administration;
- Patients who were receiving treatment in other clinical trials or less than 4 weeks from the end of the first administration in this study;
- History of serious cardiovascular and cerebrovascular diseases;
- Severe infection within 2 weeks prior to the first dose;
- Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0;
- Oversize surgery or severe trauma within 4 weeks before the first use of research drugs;
- Previously received any TNFR agonist antibody therapy, such as OX40, CD137, CD27, CD357 antibodies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SHR-2005
Only one arm with SHR-2005
|
In dose Escalation: Four dose levels are preset. The administration cycle included 6 times of induction perfusion period and 15 times of maintenance perfusion period. In indication Expansion: Indications will be selected to evaluate preliminary efficacy. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of dose limiting toxicities (DLTs)
Time Frame: From Day 1 to Day 21
|
From Day 1 to Day 21
|
|
Maximum tolerated dose (MTD)
Time Frame: From Day 1 to Day 21
|
From Day 1 to Day 21
|
|
Incidence and severity of adverse events (AEs) ([CTCAE] v5.0)
Time Frame: From Day 1 to 90 days after last dose
|
From Day 1 to 90 days after last dose
|
|
RP2D(Recommended Phase 2 dose)
Time Frame: From Day 1 to 90 days after last dose
|
From Day 1 to 90 days after last dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of response (DoR)
Time Frame: approximately within 36 months
|
Evaluated using RECIST 1.1
|
approximately within 36 months
|
|
Disease control rate (DCR)
Time Frame: approximately within 36 months
|
Evaluated using RECIST 1.1
|
approximately within 36 months
|
|
Progression-free survival (PFS)
Time Frame: approximately within 36 months
|
Evaluated using RECIST 1.1
|
approximately within 36 months
|
|
PK parameter: Tmax of SHR-2005
Time Frame: approximately 24 months
|
Time to maximum concentration of SHR-2005
|
approximately 24 months
|
|
PK parameter: Cmax of SHR-2005
Time Frame: approximately 24 months
|
Maximum concentration of SHR-2005
|
approximately 24 months
|
|
PK parameter: AUC0-∞ of SHR-2005
Time Frame: approximately 24 months
|
area under the concentration-time curve from time 0 to infinity of SHR-2005
|
approximately 24 months
|
|
Immunogenicity of SHR-2005
Time Frame: approximately 24 months
|
Anti- SHR-2005 antibody (ADA)
|
approximately 24 months
|
|
Amount_recovered and Percent_recovered
Time Frame: approximately 24 months
|
The Amount _ recovered and Percent _ recovered of SHR-2005 in urine after intravesical instillation.
|
approximately 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Male Urogenital Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Urologic Neoplasms
- Carcinoma
- Urinary Bladder Diseases
- Non-Muscle Invasive Bladder Neoplasms
- Urinary Bladder Neoplasms
Other Study ID Numbers
Other Study ID Numbers
- SHR-2005-I-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.